Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

OxStem brings in £16.9mm through early round

Executive Summary

In what some industry sources report as its Series A, OxStem Ltd. (regenerative medicines to treat various age-related diseases) raised £16.9mm ($24.4mm) from Oxford Sciences Innovation, Human Longevity, and Robert Duggan, former CEO of Pharmacyclics (prior to its 2015 acquisition by AbbVie).
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies